Items tagged with Access
Global medical students call for shift to health over trade, R&D (post)
Universities Allied for Essential Medicines is calling for new incentive models for research and development so that new treatments can be found for neglected tropical diseases to fight antibiotic resistance, and is asking that health issues supersede trade interests.
TB drugs: poor countries hanging by the thread (post)
Julius Kiiza, 26, was like many youths his age a few years back. He loved to hang out and live a good life.
Understanding barriers to rifapentine use in U.S. tuberculosis programs to inform pricing advocacy (post)
Rifapentine is an FDA-approved drug for treating tuberculosis that forms part of a regimen for TB infection. Despite clear efficacy, rifapentine's utilization by US TB programs has been lower than expected. The Treatment Action Group and the Consortium to Respond Effectively to the AIDS/TB Epidemic partnered with the National Tuberculosis Controllers Association to conduct a survey among program managers to investigate barriers to rifapentine use in order to inform ongoing advocacy efforts to increase rifapentine access. Results of the survey were recently presented as a poster at the 18th Annual Conference of the Union North America Region annual meeting.
MSF urges Prime Minister Modi to resist US political pressure to restrict global access to medicines (post)
26 September 2014, New Delhi/New York – As Indian Prime Minister Narendra Modi makes his first official visit to the United States, Médecins Sans Frontières/Doctors Without Borders (MSF) is urging the Indian government to resist U.S. pressure to drop the use of public health safeguards in its intellectual property laws, which have enabled India to become the ‘pharmacy of the developing world.’ India supplies affordable generic medicines to people and governments worldwide, including to MSF’s medical humanitarian projects, which are present in more than 60 countries.
Brifing paper: Trading Away Access to Medicines "Revisited" (post)
How the European trade agenda continues to undermine access to medicines
US-India cooperation raises hopes, concerns (post)
In this week’s highly anticipated visit to the United States by Indian Prime Minister Narendra Modi, a number of joint statements have been issued, raising hope for greater cooperation between the two countries, and some concern about the same.
No treatment Ebola, high prices for hepatitis C drugs: Time to change the pharmaceutical research system (post)
The high state of anxiety about the Ebola virus and its possible spread throughout Africa has caused fear in the world. Effective vaccines and medicines to prevent and treat Ebola do not yet exist. There are too few cases to make it profitable for pharmaceutical companies to invest in research and development (R&D), and at the end of the day those who are at risk are too poor to pay high prices.
Global financing and long-term technical assistance for multidrug-resistant tuberculosis: Scaling up access to treatment (post)
Summary Points
XDR-TB patients smuggle pills as treatment priced out of reach (post)
With treatment priced out of reach, some extensively drug-resistant tuberculosis (XDR-TB) patients face a tough choice: Break the law or die.
At WTO, experts discuss solutions to drugs innovation crisis; IP not in the list (post)
The Universities Allied for Essential Medicines (UAEM) organised a panel at the World Trade Organization Public Forum this week on new approaches in university management of intellectual property. The panel gathered a diverse panel of experts giving their take on possible solutions to less innovation and higher prices of drugs, and the role of publicly-funded research.
Page 6 of 83 · Total posts: 0
←First 5 6 7 Last→